T
Therese Giuntoli
Researcher at Washington University in St. Louis
Publications - 3
Citations - 631
Therese Giuntoli is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Breast surgery & Mastectomy. The author has an hindex of 2, co-authored 3 publications receiving 567 citations. Previous affiliations of Therese Giuntoli include University of Washington.
Papers
More filters
Journal ArticleDOI
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li,Dong Shen,Jieya Shao,Robert J. Crowder,Wenbin Liu,Aleix Prat,Xiaping He,Shuying Liu,Jeremy Hoog,Charles Lu,Li Ding,Obi L. Griffith,Christopher A. Miller,Dave Larson,Robert S. Fulton,Michelle Harrison,Thomas B. Mooney,Joshua F. McMichael,Jingqin Luo,Yu Tao,Rodrigo Franco Gonçalves,Christopher E. Schlosberg,Jeffrey F. Hiken,Laila Saied,César Sánchez,Therese Giuntoli,Caroline Bumb,Crystal Cooper,R.T. Kitchens,Austin Lin,Chanpheng Phommaly,Sherri R. Davies,Jin Zhang,Megha Shyam Kavuri,Donna McEachern,Yiyu Dong,Cynthia X. Ma,Timothy J. Pluard,Michael Naughton,Ron Bose,Rama Suresh,Reida G. McDowell,Loren S. Michel,Rebecca Aft,William E. Gillanders,Katherine DeSchryver,Richard K. Wilson,Shaomeng Wang,Gordon B. Mills,Ana M. Gonzalez-Angulo,John R. Edwards,Christopher G. Maher,Charles M. Perou,Elaine R. Mardis,Matthew J. Ellis +54 more
TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.
Journal ArticleDOI
Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial
John A. Olson,G. Thomas Budd,Lisa A. Carey,Lyndsay A. Harris,Laura J. Esserman,Gini F. Fleming,Paul K. Marcom,George S. Leight,Therese Giuntoli,Paul K. Commean,Kyongtae T. Bae,Jingqin Luo,Matthew J. Ellis +12 more
TL;DR: Better techniques to predict response, determine residual tumor burden before operation, and greater willingness to attempt BCS in responsive patients could additionally improve the rate of successful BCS.
Proceedings ArticleDOI
P1-06-13: An Amplicon-Driven Aromatase Inhibitor Response (ADAIR) Signature Provides an Orthogonal Risk Classifier for ER+ Breast Cancer.
Jianyang Luo,L-W Chang,BA Van Tine,Yu Tao,Jeremy Hoog,Therese Giuntoli,Sherri R. Davies,Jacqueline E. Snider,S Leung,Katherine DeSchryver,Craig Allred,Tammi L. Vickery,P Alldredge,Elaine R. Mardis,T. O. Nielsen,Joel Parker,Aleix Prat,CM Perou,MJ Ellis +18 more
TL;DR: The data suggest that current gene expression signatures can be improved upon through the inclusion of genes whose over-expression is linked to the gene copy number gains typical of the ER+ breast cancer genome.